CSL Limited

CSL shares rose +0.9% as the market responded relatively positively to the release of the company’s half-year results. For the six months ended 31 December, CSL reported a 19% increase in revenue to US$7,183.5m and a +10% lift in net profit after tax (NPAT) in constant currency to US$1,957m. This was driven partly by a five-month contribution from Vifor Pharma, strong growth in immunoglobulin and albumin sales, and record levels of plasma collections.